Department of Optometry, the Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China.
Department of Optometry, Hebei Medical University, Shijiazhuang 050011, China.
Contrast Media Mol Imaging. 2022 Sep 5;2022:4853481. doi: 10.1155/2022/4853481. eCollection 2022.
In order to explore the function of inhibiting the immune effect, the relationship between programmed death receptor 1 (PD-1) carrelizumab in the treatment of hepatocellular carcinoma-induced scleritis and T cell activation is investigated. A total of 120 patients with primary liver cancer treated in the department of oncology of our hospital from July 2020 to January 2022 are selected and treated with carrelizumab. According to the occurrence of PD-1 carrelizumab treatment, the patients are divided into the scleritis group and nonscleritis group. The levels of T cells, PD-1, PD-L1 proteins, and serum inflammatory factors at different time points are compared. The experimental results show that the occurrence of scleritis after liver cancer treatment with PD-1 carrelizumab is closely associated with Treg cells, the percentage of Th17 cells, the expression of PD-1, PD-L1 proteins, and inflammatory factors. It is clearly evident that PD-1 carrelizumab can increase the risk of scleritis by affecting T cell activation.
为了探索抑制免疫效果的功能，研究了程序性死亡受体 1（PD-1）卡瑞利珠单抗在治疗肝癌诱导的巩膜炎和 T 细胞激活中的作用。选择了 2020 年 7 月至 2022 年 1 月我院肿瘤科治疗的 120 例原发性肝癌患者，并用卡瑞利珠单抗进行治疗。根据 PD-1 卡瑞利珠单抗治疗的发生情况，将患者分为巩膜炎组和非巩膜炎组。比较不同时间点 T 细胞、PD-1、PD-L1 蛋白和血清炎症因子的水平。实验结果表明，PD-1 卡瑞利珠单抗治疗肝癌后发生巩膜炎与 Treg 细胞、Th17 细胞的百分比、PD-1、PD-L1 蛋白和炎症因子的表达密切相关。显然，PD-1 卡瑞利珠单抗可以通过影响 T 细胞的激活增加巩膜炎的风险。
